SCYNEXIS swung to a second-quarter profit and reiterated key development timelines for its clinical pipeline, a mix of earnings improvement and near-term trial updates that helped buoy investor sentiment. Shares of SCYNEXIS ended Monday’s session at $5.16, down 1.62%, while after-hours trading showed a gain to $5.30.
The company reported a shift to net income for the three months ended June 30, 2026, alongside an update on investigational programs including SCY-770 for autosomal dominant polycystic kidney disease (ADPKD) and SCY-247 in clinical development.
Key takeaways
- Price move: SCYNEXIS shares fell 1.62% to $5.16 on Monday, before rising to $5.30 in after-hours trading.
- Catalyst: The company reported second-quarter net profit and provided pipeline milestones for SCY-770 and SCY-247.
- Financial shift: Net income was $7.40 million, compared with a net loss in the year-ago quarter, though licensing revenue declined.
- Funding runway: Cash, cash equivalents and investments totaled $71.1 million as of June 30, with expected runway into 2029.
- Next milestones: The company plans SCY-770 topline data in the third quarter of 2026 and a Phase 2 proof-of-concept start in the fourth quarter.
What drove the second-quarter results
For the quarter ended June 30, 2026, SCYNEXIS reported net income of $7.40 million, or $0.63 per share. In the comparable period a year earlier, the company recorded a net loss of $6.89 million, or $1.11 per share.
Despite the improvement in profitability, revenue tied to licensing declined. License agreement revenue fell to $0.24 million from $1.36 million in the prior-year period. The gap suggests that the earnings swing was more influenced by factors other than licensing—such as expense dynamics or other line items not specified in the report—rather than a reversal in licensing momentum.
On liquidity, the company said that as of June 30 it held a total of $71.1 million in cash, cash equivalents and investments. Management expects this to fund operations into 2029, a key consideration for clinical-stage biotechs that must balance trial execution with financing risk.
Pipeline updates: SCY-770 and SCY-247
SCYNEXIS’s clinical and regulatory focus centers on SCY-770, an investigational AMPK activator being developed for ADPKD. The program has received Orphan Drug Designation.
For a Phase 1 study initiated on June 30, 2026, the company said the trial is characterising the food effect and defining pharmacokinetics for two dosing regimens. Those results are intended to support dose selection for a planned Phase 2 study in ADPKD patients. SCYNEXIS expects to provide topline data in the third quarter of 2026.
Looking further out, the company plans to initiate a Phase 2 proof-of-concept trial in the fourth quarter. An early efficacy readout is anticipated in the second half of 2027, placing substantial execution and data delivery emphasis on the Phase 1 outcomes first.
Separately, SCY-247—developed through SCYNEXIS’s antifungal platform—completed dosing patients in the Phase 1 study for its intravenous formulation. The company said it remains on track to report topline data in the third quarter of this year.
Management framed the update around financial capacity and operational continuity, noting that the balance sheet and cash runway should allow the company to execute across the pipeline and meet near-term milestones.
Market reaction and investor implications
The immediate share price reaction appears to reflect a combination of improving profitability and reaffirmed development timelines. While SCYNEXIS finished the regular session lower, the after-hours rise suggests investors may be weighing the profit turnaround and the clarity of near-term catalysts—particularly the expected third-quarter topline data for SCY-770 and SCY-247—against the decline in licensing revenue.
For clinical-stage companies, the market typically prices in both scientific progress and the funding outlook. With cash and investments projected to support operations into 2029, the company’s runway may reduce near-term financing pressure, potentially making it easier for investors to hold through trial timelines rather than demand immediate commercialization signals.
However, the profitability swing also comes with a caveat for holders: licensing revenue was lower year over year, which could indicate variability in external partnership economics. That factor may keep investor focus on whether product development can eventually broaden revenue sources beyond licensing.
The company’s next data events are therefore likely to be central to sentiment. For SCY-770, dose selection in support of Phase 2 depends on Phase 1 results, while for SCY-247, Phase 1 topline data may shape expectations for subsequent clinical steps.
What to watch next: SCYNEXIS plans to report topline data for the SCY-770 Phase 1 program and SCY-247 Phase 1 topline results in the third quarter of 2026, followed by a Phase 2 proof-of-concept trial initiation for SCY-770 in the fourth quarter. Investors will likely also monitor how the company’s financial performance evolves as development spending progresses and as licensing revenue trends remain under scrutiny.
